AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9398046 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma vitamin C levels
Number of subjects: 1400
Study 7706571 — intervention group
Group type: EXPERIMENTAL
Intervention: AT III concentrates administered at an initial dose of 60 U/kg followed by 10 U/kg every six hours
Number of subjects: 36
Study 7706571 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment with AT III)
Number of subjects: 36
Study 3123116 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined glyburide-insulin therapy
Number of subjects: 20
Study 3123116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31343149 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Resistance Training (VRT)
Number of subjects: 20
Study 31343149 — intervention group
Group type: COMPARATOR
Intervention: Control (soccer training alone)
Number of subjects: 20
Study 29380128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexapotide triflutate 2.5 mg transrectal injectable (FT)
Number of subjects: 995
Study 29380128 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 995
Study 27272079 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin‐BP 3.75% gel
Number of subjects: 0
Study 27272079 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.3%‐BP 2.5% gel
Number of subjects: 0
Study 24072443 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified phased RF ablation
Number of subjects: 29
Study 24072443 — intervention group
Group type: COMPARATOR
Intervention: Conventional phased RF ablation
Number of subjects: 29
Study 24072443 — intervention group
Group type: COMPARATOR
Intervention: Irrigated RF ablation
Number of subjects: 29
Study 23787293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarettes
Number of subjects: 60
Study 23787293 — intervention group
Group type: COMPARATOR
Intervention: Denicotinized cigarettes
Number of subjects: 60
Study 23787293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarettes (when told they contained nicotine)
Number of subjects: 60
Study 23787293 — intervention group
Group type: COMPARATOR
Intervention: Denicotinized cigarettes (when told they were nicotine-free)
Number of subjects: 60
Study 20839440 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM-WM treatment group
Number of subjects: 128
Study 20839440 — intervention group
Group type: COMPARATOR
Intervention: WM control group (SD-Ag)
Number of subjects: 128
Study 18031547 — intervention group
Group type: EXPERIMENTAL
Intervention: High trough plasma VPA concentrations (above 100 microg/ml for women, above 130 microg/ml for men)
Number of subjects: 265
Study 18031547 — intervention group
Group type: COMPARATOR
Intervention: Low trough plasma VPA concentrations (not explicitly defined in the abstract)
Number of subjects: 265
Study 16159735 — intervention group
Group type: EXPERIMENTAL
Intervention: Single treatment with PDT using topical methyl aminolevulinate (MAL)
Number of subjects: 211
Study 16159735 — intervention group
Group type: COMPARATOR
Intervention: Two treatments of MAL-PDT 1 week apart
Number of subjects: 211
Study 12939002 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate full occlusal loading
Number of subjects: 28
Study 12939002 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading procedure
Number of subjects: 28
Study 12939002 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Immediate and Delayed loading)
Number of subjects: 28
Study 11286374 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Resonance Therapy Music (MRT‐Music)
Number of subjects: 0
Study 11286374 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8673775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual captopril
Number of subjects: 0
Study 8673775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1438624 — intervention group
Group type: EXPERIMENTAL
Intervention: dl-fenfluramine (1.0 mg/kg)
Number of subjects: 0
Study 1438624 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 0
Study 3895409 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical streptokinase‐streptodornase (Varidase) solution
Number of subjects: 28
Study 3895409 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide
Number of subjects: 28
Study 26809253 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Detemir
Number of subjects: 42
Study 26809253 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 42
Study 26809253 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Detemir (second period)
Number of subjects: 42
Study 26809253 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine (switched to Insulin Detemir)
Number of subjects: 42
Study 24684165 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination cream with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% plus sunscreen pre-treatment for 2 weeks.
Number of subjects: 50
Study 24684165 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen alone for 2 weeks.
Number of subjects: 50
Study 24147129 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group (sham analgesic cream)
Number of subjects: 73
Study 24147129 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 73
Study 21393578 — intervention group
Group type: EXPERIMENTAL
Intervention: High glucose conditions
Number of subjects: 0
Study 21393578 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 0
Study 21393578 — intervention group
Group type: COMPARATOR
Intervention: Optimization of glycemic control
Number of subjects: 0
Study 21393578 — intervention group
Group type: COMPARATOR
Intervention: Diabetic carotid endoarterectomy specimens
Number of subjects: 0
Study 21393578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 0
Study 18339032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and selenium supplementation (Vitamin E: 140 mg alpha‐tocopherol and selenium: 200 microg)
Number of subjects: 35
Study 18339032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 17015865 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression decision support intervention
Number of subjects: 375
Study 17015865 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 375
Study 14623531 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (aromatase inhibitor) with testosterone
Number of subjects: 23
Study 14623531 — intervention group
Group type: COMPARATOR
Intervention: Placebo with testosterone
Number of subjects: 23
Study 14623531 — intervention group
Group type: COMPARATOR
Intervention: Testosterone alone (untreated boys)
Number of subjects: 23
Study 10873072 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Number of subjects: 24
Study 10873072 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg
Number of subjects: 24
Study 10873072 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (both doses combined)
Number of subjects: 24
Study 10873072 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 8826962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1441
Study 8826962 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1441
Study 1424202 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (40 mg daily for 3 months)
Number of subjects: 18
Study 1424202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2412054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin given intravenously for seven days
Number of subjects: 0
Study 2412054 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific serotonergic antagonists (oral or intravenous)
Number of subjects: 0
Study 31550800 — intervention group
Group type: COMPARATOR
Intervention: Serum D-dimer levels before delivery
Number of subjects: 785
Study 31550800 — intervention group
Group type: COMPARATOR
Intervention: Serum D-dimer levels after delivery
Number of subjects: 785
Study 31550800 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal serum D-dimer levels in AMAs
Number of subjects: 785
Study 31550800 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of VTE
Number of subjects: 785
Study 27817128 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine with vitamins B6, folic acid and B12 (Telcor® Arginin plus)
Number of subjects: 81
Study 27817128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 27567810 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 'on' bilateral DBS directed at the fornix
Number of subjects: 42
Study 27567810 — intervention group
Group type: COMPARATOR
Intervention: Sham 'off' bilateral DBS
Number of subjects: 42
Study 24752034 — intervention group
Group type: EXPERIMENTAL
Intervention: Motive-oriented therapeutic relationship (MOTR) added to general psychiatric management (GPM) treatment
Number of subjects: 85
Study 24752034 — intervention group
Group type: COMPARATOR
Intervention: General psychiatric management (GPM) treatment
Number of subjects: 85
Study 24752034 — intervention group
Group type: EXPERIMENTAL
Intervention: Motive-oriented therapeutic relationship (MOTR)
Number of subjects: 85
Study 22759549 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine gluconate (CHG) applied thrice-weekly
Number of subjects: 77
Study 22759549 — intervention group
Group type: COMPARATOR
Intervention: Control (Comfort Bath; Sage) cloths
Number of subjects: 77
Study 20454851 — intervention group
Group type: EXPERIMENTAL
Intervention: IgPro20 (20% liquid SCIG) administered weekly
Number of subjects: 49
Study 16858017 — intervention group
Group type: EXPERIMENTAL
Intervention: Light touch (LT)
Number of subjects: 40
Study 16858017 — intervention group
Group type: COMPARATOR
Intervention: No touch (NT)
Number of subjects: 40
Study 16858017 — intervention group
Group type: COMPARATOR
Intervention: Force touch (FT)
Number of subjects: 40
Study 15616024 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous leisure-time physical activity (LTPA)
Number of subjects: 487
Study 15616024 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous, structured leisure-time physical activity (LTPA)
Number of subjects: 487
Study 15616024 — intervention group
Group type: EXPERIMENTAL
Intervention: Total leisure-time physical activity (LTPA)
Number of subjects: 487
Study 15616024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity and lifestyle leisure-time physical activity (LTPA)
Number of subjects: 487
Study 12030952 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral beclometasone dipropionate (BDP) 5 mg/day plus 5‐ASA 3.2 g/day
Number of subjects: 119
Study 12030952 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 5‐ASA 3.2 g/day
Number of subjects: 119
Study 10080457 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor therapy
Number of subjects: 15104
Study 7552537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 750 mg x 2 p.o.
Number of subjects: 580
Study 7552537 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefuroxime 1.5 g x 3 i.v. on the day of surgery
Number of subjects: 580
Study 7552537 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 580
Study 1310566 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of WSDF/day consisting of psyllium husk, pectin, and guar and locust bean gums for 4 weeks
Number of subjects: 0
Study 1310566 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of WSDF/day from high-viscosity guar gum for 4 weeks
Number of subjects: 0
Study 1310566 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of WSDF/day
Number of subjects: 0
Study 1310566 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of WSDF/day
Number of subjects: 0
Study 1310566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6370619 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 21
Study 6370619 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol
Number of subjects: 21
Study 6370619 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 21
Study 31561129 — intervention group
Group type: COMPARATOR
Intervention: Elective repeat caesarean section (ERCS)
Number of subjects: 862
Study 31561129 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal birth after caesarean (VBAC)
Number of subjects: 862
Study 31561129 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor antenatal HRQoL scores
Number of subjects: 862
Study 31561129 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal readmission postpartum
Number of subjects: 862
Study 30156470 — intervention group
Group type: EXPERIMENTAL
Intervention: RMD method
Number of subjects: 0
Study 30156470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane conversion method
Number of subjects: 0
Study 30156470 — intervention group
Group type: EXPERIMENTAL
Intervention: SMD method
Number of subjects: 0
Study 30156470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness model
Number of subjects: 0
Study 27056644 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline weaker leg strength
Number of subjects: 391
Study 27056644 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk extensor endurance
Number of subjects: 391
Study 27056644 — intervention group
Group type: EXPERIMENTAL
Intervention: Slower leg velocity
Number of subjects: 391
Study 27056644 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted knee flexion motion
Number of subjects: 391
Study 25534692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordless handpiece (HP-C)
Number of subjects: 30
Study 25534692 — intervention group
Group type: COMPARATOR
Intervention: Corded handpiece (HP-A)
Number of subjects: 30
Study 25534692 — intervention group
Group type: COMPARATOR
Intervention: Corded handpiece (HP-B)
Number of subjects: 30
Study 22759841 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 401
Study 22759841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 20456060 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 : 1 mixture of propofol 1% and thiopental 2.5%
Number of subjects: 164
Study 20456060 — intervention group
Group type: COMPARATOR
Intervention: 11 : 1 mixture of propofol and 2% lidocaine
Number of subjects: 164
Study 17105779 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility criteria for major asthma RCTs
Number of subjects: 179
Study 17105779 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility criteria for major asthma RCTs (on treatment)
Number of subjects: 179
Study 16366758 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine (150 to 225 mg daily, titrated based on symptoms) + behavioral counseling + transdermal nicotine replacement therapy (22 mg/day)
Number of subjects: 147
Study 16366758 — intervention group
Group type: COMPARATOR
Intervention: placebo + behavioral counseling + transdermal nicotine replacement therapy (22 mg/day)
Number of subjects: 147
Study 12095119 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative prosthesis (IPOP)
Number of subjects: 19
Study 12095119 — intervention group
Group type: COMPARATOR
Intervention: Standard soft dressings (Control)
Number of subjects: 19
Study 10199535 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil function capacity assay measuring CD10 expression after stimulation with Staphylococcus aureus
Number of subjects: 30
Study 7546831 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin antagonists (ondansetron, granisetron, tropisetron)
Number of subjects: 0
Study 7546831 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of steroids and dopamine D2 antagonist metopimazine
Number of subjects: 0
Study 7546831 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 2270825 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape presentations followed by classroom discussion
Number of subjects: 20
Study 2270825 — intervention group
Group type: COMPARATOR
Intervention: Extended classroom discussions
Number of subjects: 20
Study 7011085 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg of hydrallazine
Number of subjects: 20
Study 7011085 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 31508798 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise training and behavioral change enhancement (BCE) program for 16 weeks with two booster sessions at 2 and 6 months after the program.
Number of subjects: 285
Study 31508798 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training and health talks only for 16 weeks.
Number of subjects: 285
Study 31508798 — intervention group
Group type: COMPARATOR
Intervention: Health talks only.
Number of subjects: 285
Study 28283340 — intervention group
Group type: EXPERIMENTAL
Intervention: IV push low dose ketamine (0.3 mg/kg)
Number of subjects: 48
Study 28283340 — intervention group
Group type: COMPARATOR
Intervention: Short infusion low dose ketamine (0.3 mg/kg)
Number of subjects: 48
Study 27009433 — intervention group
Group type: EXPERIMENTAL
Intervention: Geneva cocktail (combination of low‐dose caffeine, flurbiprofen, omeprazole, dextromethorphan, midazolam, fexofenadine, bupropion)
Number of subjects: 30
Study 27009433 — intervention group
Group type: COMPARATOR
Intervention: CYP probes administered alone
Number of subjects: 30
Study 27009433 — intervention group
Group type: EXPERIMENTAL
Intervention: Geneva cocktail
Number of subjects: 30
Study 25080037 — intervention group
Group type: EXPERIMENTAL
Intervention: Test implant (4.5-mm-diameter moderately roughened implant with a rounded 6-mm abutment)
Number of subjects: 77
Study 25080037 — intervention group
Group type: COMPARATOR
Intervention: Control implant (3.75-mm diameter as-machined implant with a conically shaped 5.5-mm abutment)
Number of subjects: 77
Study 25080037 — intervention group
Group type: EXPERIMENTAL
Intervention: Test implant
Number of subjects: 77
Study 21826454 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity sprint fatigue after running RS
Number of subjects: 11
Study 21826454 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity sprint fatigue after cycling RS
Number of subjects: 11
Study 19309367 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed dye laser (LPDL) treatment (V‐beam Perfecta, 595 nm)
Number of subjects: 13
Study 19309367 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) treatment (Ellipse Flex)
Number of subjects: 13
Study 17311692 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel (200 mg/m2) and carboplatin (AUC 6) followed by observation
Number of subjects: 37
Study 17311692 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel (200 mg/m2) and carboplatin (AUC 6) followed by radiation therapy (RT) at 5000 cGy in 25 fractions over 5 weeks
Number of subjects: 37
Study 15206988 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg fosfluconazole once daily for 14 days
Number of subjects: 0
Study 15206988 — intervention group
Group type: COMPARATOR
Intervention: 800 mg fluconazole once daily for 14 days
Number of subjects: 0
Study 15206988 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg fosfluconazole once daily for 10 days (no loading dose)
Number of subjects: 0
Study 15206988 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 1000 mg on day 1 followed by 500 mg for 9 days (one loading dose)
Number of subjects: 0
Study 15206988 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading doses of 1000 mg on days 1 and 2 followed by 500 mg for 8 days (two loading doses)
Number of subjects: 0
Study 11207642 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg)
Number of subjects: 23
Study 11207642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9740522 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneum open (n=21)
Number of subjects: 40
Study 9740522 — intervention group
Group type: COMPARATOR
Intervention: Peritoneum closed (n=19)
Number of subjects: 40
Study 7952555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung sound mapping and time‐expanded wave‐form analysis in IPF
Number of subjects: 95
Study 7952555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung sound mapping and time‐expanded wave‐form analysis in CHF
Number of subjects: 95
Study 7952555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung sound mapping and time‐expanded wave‐form analysis in COPD
Number of subjects: 95
Study 7952555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung sound mapping and time‐expanded wave‐form analysis in pneumonia (Pn)
Number of subjects: 95
Study 7952555 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without lung disease)
Number of subjects: 95
Study 2972848 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PTCA
Number of subjects: 389
Study 2972848 — intervention group
Group type: COMPARATOR
Intervention: Delayed PTCA (18-48 hours)
Number of subjects: 389
Study 29728149 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid training and staff peer support service
Number of subjects: 25
Study 29728149 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 25
Study 28938877 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (n=13)
Number of subjects: 23
Study 28938877 — intervention group
Group type: COMPARATOR
Intervention: Metformin and insulin (n=10)
Number of subjects: 23
Study 24733715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (NOT) at 3.0 l/min
Number of subjects: 51
Study 24733715 — intervention group
Group type: COMPARATOR
Intervention: No nocturnal oxygen therapy (no NOT)
Number of subjects: 51
Study 23149137 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm A (optimal variation)
Number of subjects: 195
Study 23149137 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm A (original version)
Number of subjects: 195
Study 23149137 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm B (original version)
Number of subjects: 195
Study 23149137 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm B (variation)
Number of subjects: 195